Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Experimental Medicine in Psychiatry.

AIMday banner and delegate registration desk

The University of Oxford is hosting an AIMday in Experimental Medicine in Psychiatry industry event on Wednesday 7 July 2021 (virtual event).

The AIMday format allows industry to propose challenges for one-hour roundtable discussions with groups of relevant academics and clinicians from Oxford. For academics, this is a great chance to see how your research can be applied in industry and to meet potential future collaborators. View the list of challenges put forward by industry.

Participating companies include: Lundbeck, Compass Pathways, P1vital, Circadian Therapeutics, Zogenix, Cyclica, Precision Life, Beckley Psytech, BrainBerry, Brain Cures, BrainPatch, Braxia Scientific, Psious & Ranvier Health.

The agenda also includes some exciting talks from Professor Wayne Drevets (Johnson & Johnson), Professor Catherine Harmer (University of Oxford) & Dr Adam Babbs (MRC).

Registration for Oxford researchers is now open and will close on Friday 25 June. Advance registration is essential.

Read more about the AIMday in Experimental Medicine in Psychiatry and register to attend

For more details, please contact Amira Burshan, Business Engagement Facilitator, Business Partnerships Office.

Similar stories

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

Significant scale-up investment for three Oxford spinouts

Three University of Oxford spinouts have raised significant investment to scale their companies in vehicle automation, quantum computing and medical imaging respectively.

Oxford Innovation Society celebrates pioneering biomedical research and innovation

Last month the Oxford Innovation Society (OIS) hosted an event at Pembroke College which celebrated some of the pioneering translational research and innovation coming out of the University’s Medical Sciences Division.

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

Professor Dame Sue Black to deliver 2022 Christmas Lectures

In the 2022 Christmas Lectures from the Royal Institution, DPAG's Visiting Professor of Forensic Anatomy Dame Sue Black will share secrets of forensic science.